Trevi Therapeutics
TRVI
16 hedge funds and large institutions have $88M invested in Trevi Therapeutics in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 9 closing their positions.
92% more capital invested
Capital invested by funds: $45.9M → $88M (+$42.1M)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
3.31% less ownership
Funds ownership: 78.28% → 74.97% (-3.3%)
20% less funds holding
Funds holding: 20 → 16 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$5.28M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$396K |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$141K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$88K |
| 5 |
BlackRock
New York
|
+$51.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$5.28M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.93M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$386K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$194K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$46K |
TRVI Hedge Fund Activity: Q2 2020 in Review
16 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2020, worth a combined $88M — up 92% from $45.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TRVI and 5 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was NEA Management Company, adding an estimated $5.28M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $5.28M.
- 16 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2020, down from 20 in Q1 2020.
- Funds reported $88M of Trevi Therapeutics stock for Q2 2020, up 92% quarter-over-quarter.
- 5 funds opened new Trevi Therapeutics positions in Q2 2020 and 9 closed out, a net change of -4 holders.
- The largest Trevi Therapeutics buyer in Q2 2020 was NEA Management Company, an estimated $5.28M added.
- The largest Trevi Therapeutics seller in Q2 2020 was TPG Group Holdings (SBS) Advisors, an estimated $5.28M sold.
Based on aggregated 13F filings for Q2 2020.